MAP
LXRX icon

Moody Aldrich Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Moody Aldrich Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-30,930
Closed -$509K – 98
2017
Q2 		$509K Buy
30,930
+8,475
+38% +$131K 0.63% 76
2017
Q1 		$322K Sell
22,455
-44,135
-66% -$655K 0.55% 77
2016
Q4 		$921K Buy
66,590
+24,410
+58% +$392K 0.59% 71
2016
Q3 		$762K Buy
+42,180
New +$679K 0.53% 80

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Moody Aldrich Partners's LXRX Position: Q3 2017 in Review

Moody Aldrich Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2017, closing a stake of 30,930 shares — an estimated $509K sold.

Moody Aldrich Partners first reported a position in LXRX in Q3 2016 and held it in 4 quarters. The position peaked at $921K in Q4 2016. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2017.

  • Moody Aldrich Partners reported no remaining Lexicon Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Moody Aldrich Partners sold 30,930 Lexicon Pharmaceuticals shares in Q3 2017, an estimated $509K.
  • Moody Aldrich Partners first reported a position in Lexicon Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Moody Aldrich Partners's Lexicon Pharmaceuticals position peaked at $921K in Q4 2016.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2017.

Based on Moody Aldrich Partners's 13F filing for Q3 2017, filed 13 Nov 2017.